- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Marker Therapeutics Inc (MRKR)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/17/2025: MRKR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $7.33
1 Year Target Price $7.33
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.24% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.43M USD | Price to earnings Ratio - | 1Y Target Price 7.33 |
Price to earnings Ratio - | 1Y Target Price 7.33 | ||
Volume (30-day avg) 2 | Beta 1.35 | 52 Weeks Range 0.81 - 3.95 | Updated Date 12/16/2025 |
52 Weeks Range 0.81 - 3.95 | Updated Date 12/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -173.3% |
Management Effectiveness
Return on Assets (TTM) -55.2% | Return on Equity (TTM) -110.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3834990 | Price to Sales(TTM) 3.5 |
Enterprise Value 3834990 | Price to Sales(TTM) 3.5 | ||
Enterprise Value to Revenue 0.87 | Enterprise Value to EBITDA -0.22 | Shares Outstanding 12938910 | Shares Floating 13676466 |
Shares Outstanding 12938910 | Shares Floating 13676466 | ||
Percent Insiders 5.49 | Percent Institutions 20.7 |
About Marker Therapeutics Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2014-03-25 | Co-Founder, CEO, President, Treasurer, Secretary & Director Dr. Juan F. Vera M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://markertherapeutics.com |
Full time employees 5 | Website https://markertherapeutics.com | ||
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

